Gain Therapeutics, Inc. (NASDAQ:GANX) Position Lowered by Raymond James & Associates

Raymond James & Associates reduced its position in Gain Therapeutics, Inc. (NASDAQ:GANX) by 29.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,788 shares of the company’s stock after selling 10,012 shares during the quarter. Raymond James & Associates’ holdings in Gain Therapeutics were worth $78,000 at the end of the most recent quarter.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Chardan Capital reiterated a “buy” rating and set a $6.00 target price on shares of Gain Therapeutics in a research note on Wednesday, March 27th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Gain Therapeutics in a research report on Thursday, April 25th. Finally, Oppenheimer reissued an “outperform” rating and issued a $9.00 target price on shares of Gain Therapeutics in a report on Tuesday, April 23rd.

Insider Activity

In other Gain Therapeutics news, Director Jeffrey Scott Riley acquired 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The stock was acquired at an average cost of $3.86 per share, with a total value of $115,800.00. Following the acquisition, the director now directly owns 30,000 shares of the company’s stock, valued at approximately $115,800. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 11.00% of the company’s stock.

Gain Therapeutics Stock Performance

Shares of GANX opened at $2.93 on Friday. The firm has a fifty day moving average of $3.87 and a 200-day moving average of $3.43. The company has a market cap of $52.89 million, a price-to-earnings ratio of -1.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.59 and a current ratio of 3.59. Gain Therapeutics, Inc. has a 1 year low of $2.00 and a 1 year high of $5.65.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Tuesday, March 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. As a group, equities analysts anticipate that Gain Therapeutics, Inc. will post -1.22 earnings per share for the current year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.